Exercise reduces COVID-19 risk: real-time meta analysis of 68 studies
Control
Abstract
Significantly lower risk is seen for mortality, ventilation, ICU admission, hospitalization, progression, recovery, and cases. 52 studies from 52 independent teams in 24 countries show significant
benefit.
Meta analysis using the most serious outcome reported shows
39% [33‑44%] lower risk. Results are similar for higher quality and peer-reviewed studies.
Results are very robust — in exclusion sensitivity analysis 56 of
68 studies must be excluded to avoid finding statistically significant
efficacy in pooled analysis.
Results are consistent with the overall risk of all cause mortality based on cardiorespiratory fitness — Laukkanen show RR 0.55 [0.50-0.61] for the top vs. bottom tertiles.
Most studies analyze activity levels before infection, comparing regular/moderate exercise and lower/no exercise. Risk may increase with more extreme activity levels. Exercise may also be beneficial after infection. One study shows lower COVID-19 mortality with exercise during hospitalization2.
No treatment is 100%
effective. Protocols combine safe and effective options with individual
risk/benefit analysis and monitoring.
All data and sources to reproduce this analysis are in the appendix.
Exercise for COVID-19 — Highlights
Exercise reduces risk with very high confidence for mortality, ICU admission, hospitalization, recovery, cases, and in pooled analysis, and low confidence for ventilation and progression.
9th treatment shown effective in October 2020, now with p < 0.00000000001 from 68 studies.
Real-time updates and corrections with a consistent protocol for 169 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.
Figure 1.
A. Random effects
meta-analysis. This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
B. Timeline of results in exercise studies. The marked dates indicate the time when efficacy was known with a statistically significant improvement of ≥10% from ≥3 studies for pooled outcomes and one or more specific outcome. Efficacy based on specific outcomes was delayed by 0.8 months, compared to using pooled outcomes.
Exercise can improve immune system function, reduce chronic inflammation, improve cardiovascular health, improve comorbidities, enhance lung function, reduce stress, and increase nitric oxide. Prolonged high-intensity workouts may temporarily suppress the immune system.
Insufficient physical activity is a risk factor for many diseases, is common around the world, has increasing prevalence over time, and has over two times greater prevalence in high-income countries9. For upper respiratory tract infections, research shows lower risk for moderate activity vs. a sedentary lifestyle, however risk may increase with more extreme activity levels10.
Efficacy with exercise has been shown for pneumonia11.
We analyze all significant
studies reporting COVID-19 outcomes as a function of physical activity levels.
Search methods, inclusion criteria, effect extraction criteria (more serious
outcomes have priority), all individual study data, PRISMA answers, and
statistical methods are detailed in Appendix 1. We present random
effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, peer-reviewed studies, and higher quality studies.
Table 1 summarizes the results for all studies, for peer-reviewed studies, after exclusions, and for specific outcomes.
Figure 2 plots individual results by treatment stage.
Figure 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
show forest plots for random effects meta-analysis of
all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, cases, peer reviewed studies, and long COVID.
| Improvement | Studies | Patients | Authors | |
|---|---|---|---|---|
| All studies | 39% [33‑44%] **** | 68 | 1,939,060 | 616 |
| After exclusions | 37% [32‑43%] **** | 63 | 1,937,662 | 577 |
| Peer-reviewed studiesPeer-reviewed | 38% [33‑43%] **** | 66 | 1,932,381 | 610 |
| Mortality | 48% [38‑57%] **** | 19 | 1,552,467 | 185 |
| VentilationVent. | 46% [32‑57%] **** | 2 | 43,773 | 18 |
| ICU admissionICU | 41% [35‑47%] **** | 4 | 708,149 | 32 |
| HospitalizationHosp. | 33% [25‑40%] **** | 20 | 1,020,950 | 145 |
| Recovery | 58% [41‑70%] **** | 3 | 297 | 23 |
| Cases | 23% [14‑31%] **** | 25 | 280,808 | 275 |
Figure 2. Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random effects meta-analysis.
Figure 3. Random effects meta-analysis for all studies.
This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
Figure 4. Random effects meta-analysis for mortality results.
Figure 5. Random effects meta-analysis for ventilation.
Figure 6. Random effects meta-analysis for ICU admission.
Figure 7. Random effects meta-analysis for hospitalization.
Figure 8. Random effects meta-analysis for progression.
Figure 9. Random effects meta-analysis for recovery.
Figure 10. Random effects meta-analysis for cases.
Figure 11. Random effects meta-analysis for peer reviewed studies.
Effect extraction is pre-specified, using the most serious outcome reported,
see the appendix for details.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Zeraatkar et al. analyze 356 COVID-19 trials, finding no significant
evidence that preprint results are inconsistent with peer-reviewed studies.
They also show extremely long peer-review delays, with a median of 6 months to
journal publication. A six month delay was equivalent to around 1.5 million
deaths during the first two years of the pandemic. Authors recommend using
preprint evidence, with appropriate checks for potential falsified data, which
provides higher certainty much earlier. Davidson et al. also showed no
important difference between meta analysis results of preprints and
peer-reviewed publications for COVID-19, based on 37 meta analyses including
114 trials.
Figure 12. Random effects meta-analysis for long COVID.
Effect extraction is pre-specified, using the most serious outcome reported,
see the appendix for details.
Analysis validating pooled outcomes for
COVID-19 can be found below.
To avoid bias in the selection of studies, we analyze all
non-retracted studies. Here we show the results after excluding
studies with major issues likely to alter results, non-standard studies, and
studies where very minimal detail is currently available. Our bias evaluation
is based on analysis of each study and identifying when there is a significant
chance that limitations will substantially change the outcome of the study. We
believe this can be more valuable than checklist-based approaches such as
Cochrane GRADE, which can be easily influenced by potential bias, may ignore
or underemphasize serious issues not captured in the checklists, and may
overemphasize issues unlikely to alter outcomes in specific cases (for example
certain specifics of randomization with a very large effect size and
well-matched baseline characteristics).
The studies excluded are as below.
Figure 13 shows a forest plot for random
effects meta-analysis of all studies after exclusions.
Brawner, unadjusted results with no group details.
de Souza, unadjusted results with no group details. Excluded results: mechanical ventilation.
Hegazy, unadjusted results with no group details.
Huang, unadjusted results with no group details. Excluded results: severe case.
Kontopoulou, unadjusted results with no group details.
Mohsin, unadjusted results with no group details.
Tret'yakov, unadjusted results with no group details.
Yuan, excessive unadjusted differences between groups. Excluded results: death.
Figure 13. Random effects meta-analysis for all studies after exclusions.
This plot shows pooled effects,
see the specific outcome analyses for individual outcomes.
Analysis validating pooled outcomes for
COVID-19 can be found below.
Effect extraction is pre-specified, using the most serious outcome reported.
For details see the appendix.
This section validates the use of pooled effects for COVID-19, which enables
earlier detection of efficacy, however pooled effects are no longer required
for exercise as of November 2020. Efficacy is now known based on specific outcomes. Efficacy based on specific outcomes was delayed by 0.8 months compared to using pooled outcomes.
For COVID-19, delay in clinical results translates into
additional death and morbidity, as well as additional economic and societal
damage. Combining the results of studies reporting different outcomes is
required.
There may be no mortality in a trial with low-risk patients,
however a reduction in severity or improved viral clearance may translate
into lower mortality in a high-risk population.
Different studies may report lower severity, improved recovery, and lower mortality,
and the significance may be very high when combining the results.
"The studies reported different outcomes" is not a good reason for
disregarding results.
Pooling the results of studies reporting different outcomes allows us to use
more of the available information. Logically we should, and do, use additional
information when evaluating treatments—for example dose-response and
treatment delay-response relationships provide additional evidence of efficacy
that is considered when reviewing the evidence for a treatment.
We present both specific outcome and pooled analyses.
In order to combine the results of studies reporting different outcomes we use
the most serious outcome reported in each study, based on the thesis that
improvement in the most serious outcome provides comparable measures of
efficacy for a treatment. A critical advantage of this approach is
simplicity and transparency.
There are many other ways to combine evidence for different outcomes, along
with additional evidence such as dose-response relationships, however these
increase complexity.
Trials with high-risk patients may be restricted due to ethics for treatments
that are known or expected to be effective, and they increase difficulty for
recruiting. Using less severe outcomes as a proxy for more serious outcomes
allows faster and safer collection of evidence.
For many COVID-19 treatments, a reduction in mortality logically
follows from a reduction in hospitalization, which follows from a reduction in
symptomatic cases, which follows from a reduction in PCR positivity. We can
directly test this for COVID-19.
Analysis of the the association between different outcomes across studies from
all 169
treatments we cover confirms the validity of pooled outcome analysis for COVID-19.
Figure 14 shows that lower hospitalization is very strongly associated
with lower mortality (p < 0.000000000001).
Similarly, Figure 15 shows that improved recovery is very strongly associated
with lower mortality (p < 0.000000000001).
Considering the extremes, Singh et al. show an association between viral clearance and
hospitalization or death, with p = 0.003 after excluding one large
outlier from a mutagenic treatment, and based on 44 RCTs including 52,384
patients.
Figure 16 shows that improved viral clearance is strongly associated
with fewer serious outcomes. The association is very similar to
Singh et al., with higher confidence due to the larger number of
studies. As with Singh et al., the confidence increases
when excluding the outlier treatment, from p = 0.00000011 to p = 0.0000000048.
Figure 14. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.
Figure 15. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.
Figure 14. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.
Currently, 53 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 90% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.9 months. When restricting to RCTs only, 55% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.3 months.
Figure 17 shows when treatments were found effective during the
pandemic. Pooled outcomes often resulted in earlier detection of efficacy.
Figure 17. The time when studies showed that
treatments were effective, defined as statistically significant improvement of
≥10% from ≥3 studies.
Pooled results typically show efficacy earlier than specific
outcome results. Results from all studies often shows efficacy much earlier
than when restricting to RCTs.
Results reflect conditions as used in trials to date, these depend on the
population treated, treatment delay, and treatment regimen.
Pooled analysis could hide efficacy, for example a treatment that is
beneficial for late stage patients but has no effect on viral clearance may
show no efficacy if most studies only examine viral clearance. In practice, it
is rare for a non-antiviral treatment to report viral clearance and to not
report clinical outcomes; and in practice other sources of heterogeneity such
as difference in treatment delay is more likely to hide efficacy.
Analysis validates the use of pooled effects and shows significantly faster
detection of efficacy on average.
However, as with all meta analyses, it is important to review the different
studies included. We also present individual outcome analyses, which may be
more informative for specific use cases.
Efficacy with exercise has also been shown for pneumonia11.
Most studies analyze activity levels before infection, comparing regular/moderate exercise and lower/no exercise. Risk may increase with more extreme activity levels. Exercise may also be beneficial after infection. One study shows lower COVID-19 mortality with exercise during hospitalization2.
When appropriate and within limits, exercise may be beneficial even for later stage patients, for example a non-COVID-19 RCT with critical patients under mechanical ventilation (APACHE II 22) shows lower mortality with exercise23.
SARS-CoV-2 infection and replication involves a complex
interplay of 100+ host and viral proteins and other
factors27-34, providing many therapeutic
targets.
Over 9,000 compounds have been predicted to reduce COVID-19
risk35, either by directly
minimizing infection or replication, by supporting immune system function, or
by minimizing secondary complications.
Exercise can improve immune system function, reduce chronic inflammation, improve cardiovascular health, improve comorbidities, enhance lung function, reduce stress, and increase nitric oxide. Prolonged high-intensity workouts may temporarily suppress the immune system.
Figure 18 shows an overview of the results for exercise
in the context of multiple COVID-19 treatments, and Figure 19 shows a plot
of efficacy vs. cost for COVID-19 treatments.
Figure 18.
Scatter plot showing results within the context of multiple COVID-19 treatments.
Diamonds shows the results of random effects meta-analysis.
0.6% of 9,000+ proposed treatments show efficacy36.
Figure 19. Efficacy vs. cost for COVID-19 treatments.
Exercise can improve immune system function, reduce chronic inflammation, improve cardiovascular health, improve comorbidities, enhance lung function, reduce stress, and increase nitric oxide. Prolonged high-intensity workouts may temporarily suppress the immune system.
More physically active people have reduced risk for COVID-19.
Significantly lower risk is seen for mortality, ventilation, ICU admission, hospitalization, progression, recovery, and cases. 52 studies from 52 independent teams in 24 countries show significant
benefit.
Meta analysis using the most serious outcome reported shows
39% [33‑44%] lower risk. Results are similar for higher quality and peer-reviewed studies.
Results are very robust — in exclusion sensitivity analysis 56 of
68 studies must be excluded to avoid finding statistically significant
efficacy in pooled analysis.
Results are consistent with the overall risk of all cause mortality based on cardiorespiratory fitness — Laukkanen show RR 0.55 [0.50-0.61] for the top vs. bottom tertiles.
Most studies analyze activity levels before infection, comparing regular/moderate exercise and lower/no exercise. Risk may increase with more extreme activity levels. Exercise may also be beneficial after infection. One study shows lower COVID-19 mortality with exercise during hospitalization2.
6 other meta analyses show significant improvements with exercise for mortality3-7, ICU admission3, hospitalization3,4,7,8, severity4-6, and cases4.
Efficacy with exercise has also been shown for pneumonia11.
Prospective study of 1,559,187 men in Sweden with cardiorespiratory fitness levels measured on military conscription, showing high cardiorespiratory fitness associated with lower risk of COVID-19 hospitalization, ICU admission, and death.
Retrospective 468,569 adults in the UK, showing significantly lower COVID-19 mortality with physical activity.
Retrospective 10,000 adults in Qatar, showing lower risk of COVID-19 cases with increased leisure time physical activity, without statistical significance. Authors do not analyze COVID-19 severity.
Retrospective 142 patients in Saudi Arabia, showing no significant difference in cases with physical activity.
Retrospective 39 hospitalized COVID-19 survivors >60 years old, showing shorter hospitalization for patients with active lifestyles before COVID-19 symptoms.
Retrospective 234 COVID-19 cases in the United Arab Emirates, showing lower risk of mortality with increased physical activity.
Retrospective 2,830 people in the USA, showing lower risk of COVID-19 with a history of moderate/vigorous exercise.
Retrospective 1,544 participants in Slovakia, showing a lower risk of more severe COVID-19 for physically active participants, without statistical significance.
Retrospective 263 COVID+ patients, showing lower hospitalization with higher self-reported cardiorespiratory fitness, but no significant differences for physical activity. Participants in the study were healthier and more fit than the general population.
Retrospective 246 COVID-19 patients in the USA, showing the risk of hospitalization inversely associated with maximal exercise capacity. Adjusted results are only provided for MET as a continuous variable.
Case control study with 307 severe COVID-19 ICU patients and 307 matched COVID-19 outpatients in Brazil, showing significantly higher risk of severe cases with low physical activity.
Retrospective 6,288 COVID+ patients and 125,772 matched controls in South Korea, showing significantly lower risk of COVID-19 infection and mortality with higher physical activity.
Prospective study of 2,690 adults in the UK Biobank showing lower cardiorespiritory fitness associated with COVID-19 mortality.
Retrospective survey of 938 COVID-19 recovered patients in Brazil, showing lower hospitalization with physical activity. NCT04396353.
Retrospective 857 severe COVID-19 cases and matched controls in Sweden, showing lower risk of severe COVID-19 with higher cardiorespiratory fitness.
Retrospective 439 severe COVID-19 hospitalized patients with hypertension, 201 receiving a supervised exercise program, showing significantly lower mortality with exercise. Exercise included of aerobic, breathing, and musculoskeletal exercises, 3 to 4 times per week. There were significantly more control patients on beta-adrenergic blockers and thiazide diuretics.
There are many possible mechanisms of action, including improved circulation, stress reduction, hormone regulation, improved sleep, increased antioxidant levels, and increased nitric oxide levels in the respiratory system. Over-exercising may be detrimental and lead to impaired immune function.
There are many possible mechanisms of action, including improved circulation, stress reduction, hormone regulation, improved sleep, increased antioxidant levels, and increased nitric oxide levels in the respiratory system. Over-exercising may be detrimental and lead to impaired immune function.
Analysis of 237 COVID-19 patients in Brazil, showing lower risk of long COVID with physical activity.
Retrospective 3,038 bariatric surgery patients in Israel, showing higher risk of SARS-CoV-2 infection with vitamin D deficiency, and lower risk with physical activity.
Case control study in China with 105 cases and 210 matched controls, showing COVID-19 cases associated with physical activity ≥5 times per week. Authors note that people may choose gyms for exercise in winter, leading to higher exposure risk.
Retrospective survey of 1,997 college students in the USA, showing no significant difference in COVID-19 cases with exercise in unadjusted results.
Retrospective 113,075 people in Israel, showing lower risk of COVID-19 cases with physical activity and a dose dependent response.
Retrospective 4,694 COVID-19 patients in Iran, showing lower risk of hospitalization and mortality with regular sports participation.
Retrospective 300 participants in Palestine, showing lower risk of hospitalization with physical activity, without statistical significance.
UK Biobank retrospective analysis of 387,109 people, showing lower risk of COVID-19 hospitalization with physical activity.
Prospective UK Biobank analysis, showing a history of low physical activity associated with COVID-19 mortality.
Retrospective 68 COVID-19 patients showing physical activity and healthier nutrition associated with lower COVID-19 severity.
Analysis of 200 mild and moderate COVID-19 outpatients showing an association between higher ESSAP scores (measuring exercise, sugar and prebiotic consumption, sleep, and antibiotic use) and milder COVID-19 disease. Authors find increased risk with daily yogurt containing probiotics. Probiotic intake based on yogurt only may be inaccurate. Authors hypothesize that commercial yogurt products may not contain sufficient beneficial bacteria or may be contaminated. Other research shows that probiotic food labels are often misleading—of 26 probiotic foods tested, only 5 contained Bifidobacterium in sufficient concentration for exhibiting a therapeutic effect37. For sleep, authors compare <8 hours and ≥8 hours, while sleep for less than or longer than a recommended range may indicate increased risk.
UK Biobank retrospective 235,928 participants using walking pace as a proxy for physical fitness, showing lower risk of COVID-19 hospitalization with an average vs. slow walking pace.
Prospective survey-based study with 15,227 people in the UK, showing reduced risk of COVID-19 cases with lower impact physical activity.
Retrospective 164 COVID-19 patients and 188 controls in China, showing lower risk of cases with regular exercise.
Retrospective 568 convalescent COVID-19 patients in Poland, showing lower risk of severe cases with regular physical activity in the 3 months before COVID-19.
Retrospective 66 hospitalized COVID-19 patients in Greece, showing significantly improved recovery with a history of exercise in unadjusted results. Exercise after hospitalization was also associated with lower levels of dyspnea one month post hospitalization.
Retrospective 420 people in Spain, showing lower risk of COVID-19 hospitalization with a history of physical activity.
Retrospective 212,768 adults in South Korea, showing lower risk of COVID-19 cases, severity, and mortality with physical activity. Notably, results for aerobic and muscle strengthening activities combined were much better than results for either one in isolation.
Analysis of 241 adults >65yo in Belgium, showing lower risk of COVID-19 with a history of physical activity.
Mendelian randomization study showing lower risk of severe COVID-19 with physical activity.
Prospective survey analysis of 28,575 people in 99 countries, showing a lower risk of COVID-19 with a exercise, without statistical significance.
Retrospective 5,712 COVID-19 patients in the USA, showing higher risk of COVID-19 hospitalization with a history of physical inactivity.
Retrospective 452 participants in Luxembourg, showing lower risk of moderate cases with higher physical activity.
Retrospective 3,139 adults >50 in Europe, with 66 COVID-19 hospitalizations, showing lower risk of hospitalization with higher physical activity and with higher muscle strength. Note that model 2 includes muscle strength which is correlated with physical activity38.
Prospective survey based study with 14,335 participants, showing lower risk of viral symptoms with regular exercise.
Retrospective 1,500 COVID+ patients in Bangladesh, showing lower risk of severe cases with regular exercise in unadjusted results.
Prospective study of 61,557 adults aged 45+ years showing reduced risk of COVID-19 diagnosis and hospitalization for those meeting physical activity guidelines of ≥7.5 MET-hours/week before the pandemic compared to inactive individuals.
Analysis of 3,947 participants in Vietnam, showing significantly lower risk of COVID-19-like symptoms with physical activity and with a healthy diet. The combination of being physically active and eating healthy reduced risk further compared to either alone. The analyzed period was Feb 14 to Mar 2, 2020, which may have been before testing was widely available.
Retrospective 4,363 COVID-19 patients and 67,125 controls in South Korea, showing higher risk of mortality and cases with insufficient physical activity.
Retrospective 1,811 COVID-19 patients in the UK, showing lower risk of self-reported long COVID with 3+ hours of exercise per week in the month before infection, without statistical significance (p=0.16).
Retrospective 5,197 Greek adults over 65. After adjustment for confounders, COVID-19 infection was independently associated with poor sleep, low physical activity, low Mediterranean diet adherence, living in urban areas, smoking, obesity, depression, anxiety, stress, and poor health-related quality of life.
Retrospective 4,476 participants in Brazil, showing lower risk of COVID-19 cases with a history of physical activity, statistically significant only for those following specific practices to protect against COVID-19.
Retrospective 1,847 COVID+ patients in Poland, showing no significant difference in moderate/severe cases with physical activity. Hospitalized patients were excluded.
Retrospective 546 COVID+ patients in the USA, showing lower risk of hospitalization with higher frequency of strength training, without statistical significance.
Retrospective 2,919 non-hospitalized COVID-19 patients in Brazil showing remaining physically active before and after COVID-19 infection reduces the probability of experiencing long COVID symptoms, particularly those affecting the musculoskeletal, neurological and respiratory systems.
Retrospective 904 patients in Sweden, showing higher risk of COVID-19-like symptoms with poor muscle strength. Risk was slightly higher for physical inactivity, without statistical significance.
Retrospective 520 COVID-19 patients in Spain, showing significantly lower mortality with a history of physical activity.
Retrospective 48,440 COVID-19 patients in the USA, showing significantly lower mortality, ICU admission, and hospitalization with exercise.
Retrospective 29,875 university staff and students in Spain, 3,662 with data, showing lower risk of COVID-19 symptoms for people that exercise. Exercise more than 5 days/week was the most protective, and intense exercise was more effective than moderate exercise.
Retrospective 5,338 individuals with confirmed contact with a COVID-19 patient, showing lower risk of COVID-19 with exercise.
Retrospective 65,361 COVID-19 patients in South Africa, showing significantly lower hospitalization, ICU admission, ventilation, and mortality with exercise.
Prospective study of 131 hospitalized patients in Poland, showing lower mortality and improved recovery with a history of higher physical activity.
Retrospective 206 patients in Iran, showing COVID-19 disease severity associated with lower physical activity.
Retrospective 293 COVID+ patients in Russia, showing lower risk of severe COVID-19 for individuals who regularly practice aerobic training in unadjusted results.
Retrospective 4,868 elderly COVID-19 patients in Japan, showing higher risk of severe cases with poor physical activity status.
Prospective study of 68,896 UK Biobank participants with COVID-19 showing adherence to a healthy lifestyle prior to infection, characterized by 10 factors including adequate physical activity and sleep, not smoking, and a healthy BMI, was associated with a significantly lower risk of mortality, hospitalization, and post-COVID multisystem sequelae. Risk decreased monotonically for increasing numbers of healthy lifestyle factors from 5-10. Reduced risks were evident across cardiovascular, metabolic, neurologic, respiratory, and other disorders over 210 days following infection, during both acute and post-acute phases, regardless of age, sex, ethnicity, test setting, vaccination status, or SARS-CoV-2 variant.
Prospective analysis of 32,249 women, showing lower risk of PASC with a healthy lifestyle, in a dose-dependent manner. Participants with 5 or 6 healthy lifestyle factors had significantly lower COVID-19 hospitalization and PASC. BMI and sleep were independently associated with risk of PASC.
UK Biobank retrospective 412,596 people, showing severe COVID-19 and COVID-19 mortality inversely associated with self-reported walking pace.
Retrospective 194,191 COVID-19 patients in the USA, showing lower risk of hospitalization and mortality with physical activity, with a dose response relationship.
Retrospective 164 COVID-19 patients in China, showing physical inactivity associated with an increased risk of severe COVID-19.
UK Biobank retrospective showing significantly lower COVID-19 cases with objectively measured physical activity.
Retrospective 100 COVID-19 patients in Bosnia and Herzegovina, showing lower symptom severity and faster recovery with a history of regular physical activity.
We perform ongoing searches of PubMed, medRxiv, Europe PMC,
ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research
Square, ScienceDirect, Oxford University Press, the reference lists of other
studies and meta-analyses, and submissions to the site c19early.org.
Search terms are (exercise OR "physical activity") AND COVID-19. Automated searches are performed twice daily, with all matches reviewed for inclusion.
All studies regarding the use of exercise for COVID-19 that report
a comparison with a control group are included in the main analysis.
Sensitivity analysis is performed, excluding studies with major issues,
epidemiological studies, and studies with minimal available information.
Studies with major unexplained data issues, for example major outcome data that
is impossible to be correct with no response from the authors, are excluded.
This is a living analysis and is updated regularly.
We extracted effect sizes and associated data from all studies.
If studies report multiple kinds of effects then the most serious
outcome is used in pooled analysis, while other outcomes are included in the
outcome specific analyses. For example, if effects for mortality and cases are
both reported, the effect for mortality is used, this may be different to the
effect that a study focused on.
If symptomatic
results are reported at multiple times, we used the latest time, for example
if mortality results are provided at 14 days and 28 days, the results at 28
days have preference. Mortality alone is preferred over combined outcomes.
Outcomes with zero events in both arms are not used, the next most serious
outcome with one or more events is used. For example, in low-risk populations
with no mortality, a reduction in mortality with treatment is not possible,
however a reduction in hospitalization, for example, is still valuable.
Clinical outcomes are considered more important than viral test status. When
basically all patients recover in both treatment and control groups,
preference for viral clearance and recovery is given to results mid-recovery
where available. After most or all patients have recovered there is little or
no room for an effective treatment to do better, however faster recovery is
valuable.
If only individual symptom data is available, the most serious symptom has
priority, for example difficulty breathing or low SpO2 is more
important than cough.
When results provide an odds ratio, we compute the relative risk when
possible, or convert to a relative risk according to39.
Reported confidence intervals and p-values were used when available,
using adjusted values when provided. If multiple types of adjustments are
reported propensity score matching and multivariable regression has preference
over propensity score matching or weighting, which has preference over
multivariable regression. Adjusted results have preference over unadjusted
results for a more serious outcome when the adjustments significantly alter
results. When needed, conversion between reported p-values and
confidence intervals followed Altman, Altman (B), and Fisher's exact
test was used to calculate p-values for event data. If continuity
correction for zero values is required, we use the reciprocal of the opposite
arm with the sum of the correction factors equal to 142.
Results are expressed with RR < 1.0 favoring treatment, and using the risk of
a negative outcome when applicable (for example, the risk of death rather than
the risk of survival). If studies only report relative continuous values such
as relative times, the ratio of the time for the treatment group versus the
time for the control group is used. Calculations are done in Python
(3.13.3) with
scipy (1.15.3), pythonmeta (1.26), numpy (2.2.6), statsmodels (0.14.4), and plotly (6.0.1).
Forest plots are computed using PythonMeta43
with the DerSimonian and Laird random effects model (the fixed effect
assumption is not plausible in this case) and inverse variance weighting.
Results are presented with 95% confidence intervals. Heterogeneity among studies was
assessed using the I2 statistic.
Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor
(4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome.
For all statistical tests, a p-value less than 0.05 was considered statistically significant.
Grobid 0.8.2 is used to parse PDF documents.
We have classified studies as early treatment if most patients
are not already at a severe stage at the time of treatment (for example based
on oxygen status or lung involvement), and treatment started within 5 days of
the onset of symptoms. If studies contain a mix of early treatment and late
treatment patients, we consider the treatment time of patients contributing
most to the events (for example, consider a study where most patients are
treated early but late treatment patients are included, and all mortality
events were observed with late treatment patients).
We note that a shorter time may be preferable. Antivirals are typically only
considered effective when used within a shorter timeframe, for example 0-36 or
0-48 hours for oseltamivir, with longer delays not being effective44,45.
We received no funding, this research is done in our spare
time. We have no affiliations with any pharmaceutical companies or political
parties.
A summary of study results is below. Please submit
updates and corrections at https://c19early.org/exmeta.html.
Effect extraction follows pre-specified rules as detailed above
and gives priority to more serious outcomes.
For pooled analyses, the first (most serious) outcome is used, which may
differ from the effect a paper focuses on.
Other outcomes are used in outcome specific analyses.
| Fernandez, 2/2/2023, retrospective, Chile, peer-reviewed, 10 authors. | risk of death, 47.5% lower, RR 0.53, p = 0.02, high activity levels 16 of 201 (8.0%), low activity levels 62 of 238 (26.1%), NNT 5.5, adjusted per study, odds ratio converted to relative risk, multivariable. |
Effect extraction follows pre-specified rules as detailed above
and gives priority to more serious outcomes.
For pooled analyses, the first (most serious) outcome is used, which may
differ from the effect a paper focuses on.
Other outcomes are used in outcome specific analyses.
| af Geijerstam, 7/5/2021, prospective, Sweden, peer-reviewed, 9 authors, study period March 2020 - September 2020. | risk of death, 50.0% lower, OR 0.50, p = 0.005, high vs. low fitness, model 7, RR approximated with OR. |
| risk of ICU admission, 40.0% lower, OR 0.60, p < 0.001, high vs. low fitness, model 7, RR approximated with OR. | |
| risk of hospitalization, 27.0% lower, OR 0.73, p < 0.001, high vs. low fitness, model 7, RR approximated with OR. | |
| Ahmadi, 8/31/2021, retrospective, United Kingdom, peer-reviewed, 5 authors. | risk of death, 30.0% lower, RR 0.70, p = 0.005, adjusted per study, sufficient vs. inactive, model 2, multivariable. |
| Akbar, 11/7/2023, retrospective, Qatar, peer-reviewed, mean age 40.3, 9 authors, study period March 2020 - September 2020. | risk of case, 7.0% lower, OR 0.93, p = 0.40, high activity levels 3,333, low activity levels 3,333, adjusted per study, T3 vs. T1, multivariable, model 2, RR approximated with OR. |
| Almansour, 2/17/2022, retrospective, Saudi Arabia, peer-reviewed, 12 authors, study period April 2020 - June 2020. | risk of case, 5.7% lower, RR 0.94, p = 0.85, high activity levels 35 of 71 (49.3%), low activity levels 38 of 71 (53.5%), NNT 24, adjusted per study, odds ratio converted to relative risk, multivariable. |
| Antunes, 6/11/2022, retrospective, Brazil, peer-reviewed, survey, 5 authors, study period September 2020 - December 2020. | risk of ICU admission, 80.2% lower, RR 0.20, p = 0.06, high activity levels 1 of 14 (7.1%), low activity levels 9 of 25 (36.0%), NNT 3.5. |
| risk of miscellaneous, 40.5% lower, RR 0.60, p = 0.48, high activity levels 3 of 14 (21.4%), low activity levels 9 of 25 (36.0%), NNT 6.9, CT abnormalities >50%. | |
| risk of miscellaneous, 72.5% lower, RR 0.27, p = 0.04, high activity levels 2 of 14 (14.3%), low activity levels 13 of 25 (52.0%), NNT 2.7, CT abnormalities 25-50%. | |
| hospitalization time, 43.4% lower, relative time 0.57, p = 0.03, high activity levels 14, low activity levels 25. | |
| miscellaneous, 25.5% lower, relative time 0.74, p = 0.02, high activity levels 14, low activity levels 25. | |
| Baynouna AlKetbi, 8/23/2021, retrospective, United Arab Emirates, peer-reviewed, 16 authors. | risk of death, 98.5% lower, OR 0.01, p = 0.049, adjusted per study, multivariable, RR approximated with OR. |
| Beydoun, 3/12/2022, retrospective, USA, peer-reviewed, survey, 7 authors. | risk of case, 43.0% lower, OR 0.57, p = 0.05, high activity levels 1,710, low activity levels 448, adjusted per study, multivariable, >1/week vs. none, model 2, RR approximated with OR. |
| risk of case, 62.0% lower, OR 0.38, p = 0.010, high activity levels 672, low activity levels 448, adjusted per study, multivariable, 1-4/mon vs. none, model 2, RR approximated with OR. | |
| Bielik, 7/4/2021, retrospective, Slovakia, peer-reviewed, survey, 3 authors, study period 7 December, 2020 - 12 December, 2020. | risk of moderate case, 30.4% lower, RR 0.70, p = 0.10, high activity levels 775, low activity levels 365, adjusted per study, physically active group. |
| risk of case, 9.1% higher, RR 1.09, p = 0.36, high activity levels 775, low activity levels 365, adjusted per study, physically active group. | |
| Brandenburg, 7/1/2021, retrospective, multiple countries, peer-reviewed, survey, 4 authors. | risk of hospitalization, 6.0% higher, OR 1.06, p = 0.60, high activity levels 102, low activity levels 39, adjusted per study, multivariable, PA, >1h vigorous vs. no/low, RR approximated with OR. |
| risk of hospitalization, 78.0% lower, OR 0.22, p = 0.05, high activity levels 177, low activity levels 34, adjusted per study, multivariable, CRF, 6.2-8.7 vs. >10, RR approximated with OR. | |
| risk of hospitalization, 64.0% lower, OR 0.36, p = 0.04, high activity levels 97, low activity levels 34, adjusted per study, multivariable, CRF, 8.7-10 vs. >10, RR approximated with OR. | |
| risk of severe case, 35.0% lower, OR 0.65, p = 0.30, high activity levels 102, low activity levels 39, adjusted per study, multivariable, PA, >1h vigorous vs. no/low, RR approximated with OR. | |
| risk of severe case, 24.0% lower, OR 0.76, p = 0.60, high activity levels 52, low activity levels 34, adjusted per study, multivariable, CRF, 4.4-6.2 vs. >10, RR approximated with OR. | |
| Brawner, 10/10/2020, retrospective, USA, peer-reviewed, 10 authors, study period 29 February, 2020 - 30 May, 2020, excluded in exclusion analyses: unadjusted results with no group details. | risk of hospitalization, 74.2% lower, OR 0.26, p = 0.001, unadjusted, inverted to make OR<1 favor high activity levels, highest fitness quartile vs. lowest fitness quartile, RR approximated with OR. |
| Cardoso, 5/9/2023, retrospective, Brazil, peer-reviewed, 6 authors, study period April 2020 - February 2022. | risk of severe case, 73.0% lower, OR 0.27, p < 0.001, high activity levels 307, low activity levels 307, adjusted per study, inverted to make OR<1 favor high activity levels, case control OR, moderate/high vs. low physical activity, multivariable. |
| Cho, 4/6/2021, retrospective, South Korea, peer-reviewed, 9 authors. | risk of death, 53.0% lower, OR 0.47, p = 0.01, high activity levels 17 of 48 (35.4%) cases, 3,223 of 4,536 (71.1%) controls, case control OR, moderate to vigorous vs. inactive. |
| risk of case, 10.0% lower, OR 0.90, p < 0.001, high activity levels 3,223 of 4,536 (71.1%) cases, 68,609 of 92,587 (74.1%) controls, NNT 142, case control OR, moderate to vigorous vs. inactive. | |
| Christensen, 5/5/2021, prospective, United Kingdom, peer-reviewed, 5 authors, study period 16 March, 2020 - 26 July, 2020. | risk of death, 63.0% lower, RR 0.37, p = 0.02, high activity levels 543, low activity levels 529, adjusted per study, high fitness vs. low fitness, multivariable. |
| risk of case, 23.0% lower, RR 0.77, p = 0.20, high activity levels 55 of 543 (10.1%), low activity levels 77 of 529 (14.6%), NNT 23, adjusted per study, high fitness vs. low fitness, multivariable. | |
| de Souza, 9/30/2021, retrospective, Brazil, peer-reviewed, 8 authors, study period June 2020 - August 2020, trial NCT04396353 (history). | risk of mechanical ventilation, 73.2% lower, RR 0.27, p = 0.07, high activity levels 3 of 611 (0.5%), low activity levels 6 of 327 (1.8%), NNT 74, unadjusted, excluded in exclusion analyses: unadjusted results with no group details. |
| risk of hospitalization, 34.3% lower, RR 0.66, p = 0.046, high activity levels 49 of 611 (8.0%), low activity levels 42 of 327 (12.8%), NNT 21, adjusted per study, sufficient vs. insufficient, model 3, multivariable. | |
| Ekblom-Bak, 10/19/2021, retrospective, Sweden, peer-reviewed, 13 authors. | risk of severe case, 47.6% lower, OR 0.52, p = 0.02, inverted to make OR<1 favor high activity levels, case control OR, model 3, high vs. very low CRF. |
| Feter, 6/13/2023, retrospective, Brazil, peer-reviewed, survey, mean age 37.1, 17 authors. | risk of PASC, 26.0% lower, RR 0.74, p = 0.02, high activity levels 52, low activity levels 95, adjusted per study, before and during pandemic, multivariable. |
| risk of PASC, 17.0% lower, RR 0.83, p = 0.04, high activity levels 67, low activity levels 170, adjusted per study, during pandemic, multivariable. | |
| Frish, 6/15/2023, retrospective, Israel, peer-reviewed, 7 authors, study period 1 February, 2020 - 31 December, 2020. | risk of case, 53.0% lower, OR 0.47, p = 0.04, high activity levels 212, low activity levels 1,202, adjusted per study, >3 times per week vs. none, multivariable, RR approximated with OR. |
| Gao, 11/5/2020, retrospective, China, peer-reviewed, survey, median age 55.0, 11 authors, study period 10 February, 2020 - 1 March, 2020. | risk of case, 105.0% higher, HR 2.05, p < 0.001, high activity levels 59 of 105 (56.2%) cases, 69 of 210 (32.9%) controls, case control OR, Cox proportional hazards. |
| Gilley, 2/10/2022, retrospective, USA, peer-reviewed, survey, 21 authors, study period September 2020 - December 2020, trial NCT04766788 (history). | risk of case, 41.8% higher, RR 1.42, p = 0.55, high activity levels 172 of 1,917 (9.0%), low activity levels 5 of 79 (6.3%), unadjusted. |
| Green, 11/7/2022, retrospective, Israel, peer-reviewed, 9 authors, study period 1 February, 2020 - 31 December, 2020. | risk of case, 41.7% lower, RR 0.58, p < 0.001, high activity levels 1,267 of 11,144 (11.4%), low activity levels 16,198 of 101,931 (15.9%), adjusted per study, odds ratio converted to relative risk, >3 times per week vs. none, multivariable. |
| Halabchi (B), 12/1/2020, retrospective, Iran, peer-reviewed, 8 authors. | risk of death, 88.8% lower, RR 0.11, p = 0.08, high activity levels 0 of 249 (0.0%), low activity levels 79 of 4,445 (1.8%), NNT 56, adjusted per study, odds ratio converted to relative risk, multivariable. |
| risk of hospitalization, 28.3% lower, RR 0.72, p = 0.04, high activity levels 30 of 249 (12.0%), low activity levels 878 of 4,445 (19.8%), adjusted per study, odds ratio converted to relative risk, multivariable. | |
| Hamdan, 12/23/2021, retrospective, Palestine, peer-reviewed, survey, mean age 30.5, 7 authors. | risk of hospitalization, 16.4% lower, RR 0.84, p = 0.53, high activity levels 22 of 128 (17.2%), low activity levels 37 of 172 (21.5%), NNT 23, adjusted per study, odds ratio converted to relative risk, multivariable. |
| Hamer, 7/31/2020, retrospective, United Kingdom, peer-reviewed, 4 authors. | risk of hospitalization, 27.5% lower, RR 0.72, p < 0.001, adjusted per study, inverted to make RR<1 favor high activity levels, model 2, sufficient vs. no activity, multivariable. |
| risk of hospitalization, 33.8% lower, RR 0.66, p < 0.001, adjusted per study, inverted to make RR<1 favor high activity levels, model 1, sufficient vs. no activity, multivariable. | |
| Hamrouni, 11/3/2021, prospective, United Kingdom, peer-reviewed, 5 authors. | risk of death, 29.0% lower, RR 0.71, p = 0.009, high activity levels 138 of 106,006 (0.1%), low activity levels 109 of 47,827 (0.2%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, high vs. low physical activity, multivariable. |
| Hegazy, 10/2/2023, retrospective, Egypt, peer-reviewed, 7 authors, study period May 2021 - February 2022, trial NCT04447144 (history), excluded in exclusion analyses: unadjusted results with no group details. | risk of moderate case, 54.0% lower, RR 0.46, p = 0.010, high activity levels 15 of 50 (30.0%), low activity levels 15 of 23 (65.2%), NNT 2.8, active vs. inactive. |
| risk of moderate case, 97.1% lower, RR 0.03, p = 0.02, high activity levels 0 of 7 (0.0%), low activity levels 30 of 61 (49.2%), NNT 2.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate vs. low/inactive. | |
| Hegazy (B), 6/7/2021, retrospective, Egypt, peer-reviewed, 10 authors, trial NCT04447144 (history). | risk of moderate/severe case, 45.6% lower, RR 0.54, p = 0.11, high activity levels 24 of 82 (29.3%), low activity levels 7 of 13 (53.8%), NNT 4.1, >10min/day vs. none. |
| Ho, 11/19/2020, retrospective, United Kingdom, peer-reviewed, survey, 13 authors. | risk of hospitalization, 34.6% lower, RR 0.65, p = 0.007, high activity levels 213 of 123,588 (0.2%), low activity levels 59 of 14,887 (0.4%), adjusted per study, inverted to make RR<1 favor high activity levels, model 2, average vs. slow walking pace, multivariable. |
| Holt, 3/30/2021, prospective, United Kingdom, peer-reviewed, 34 authors, study period 1 May, 2020 - 5 February, 2021, trial NCT04330599 (history) (COVIDENCE UK). | risk of case, 17.0% lower, OR 0.83, p = 0.18, adjusted per study, fully adjusted, ≥2 hours lower impact physical activity vs. 0 hours, RR approximated with OR. |
| Huang, 11/30/2021, retrospective, China, peer-reviewed, survey, 5 authors, study period 10 February, 2020 - 28 March, 2020. | risk of severe case, 46.8% lower, RR 0.53, p = 0.18, high activity levels 7 of 74 (9.5%), low activity levels 16 of 90 (17.8%), NNT 12, unadjusted, exercise habit, ≥1 time per week, excluded in exclusion analyses: unadjusted results with no group details. |
| risk of severe case, 8.0% lower, RR 0.92, p = 1.00, high activity levels 3 of 23 (13.0%), low activity levels 20 of 141 (14.2%), NNT 88, unadjusted, ≥30 minutes ≥3 times per week, excluded in exclusion analyses: unadjusted results with no group details. | |
| risk of case, 65.9% lower, OR 0.34, p = 0.004, adjusted per study, inverted to make OR<1 favor high activity levels, case control OR, regular exercise, multivariable. | |
| Kapusta, 12/12/2022, retrospective, Poland, peer-reviewed, survey, mean age 70.4, 7 authors, study period 1 March, 2020 - 30 August, 2020, trial NCT05018052 (history). | risk of severe case, 70.9% lower, OR 0.29, p = 0.001, high activity levels 181, low activity levels 387, inverted to make OR<1 favor high activity levels, RR approximated with OR. |
| Kontopoulou, 4/17/2022, retrospective, Greece, peer-reviewed, survey, 4 authors, study period November 2020 - December 2020, excluded in exclusion analyses: unadjusted results with no group details. | recovery time, 66.2% lower, relative time 0.34, p < 0.001, high activity levels mean 22.0 (±14.0) n=42, low activity levels mean 65.0 (±32.0) n=24. |
| relative dyspnea after hospitalization, 66.7% better, RR 0.33, p < 0.001, high activity levels mean 1.0 (±1.0) n=42, low activity levels mean 3.0 (±1.0) n=24, inverted to make RR<1 favor high activity levels. | |
| Latorre-Román, 6/15/2021, retrospective, Spain, peer-reviewed, survey, 7 authors. | risk of hospitalization, 76.0% lower, OR 0.24, p = 0.05, moderate physical activity, >150 min per week, RR approximated with OR. |
| risk of hospitalization, 87.0% lower, OR 0.13, p = 0.07, moderate physical activity, 30-150 min per week, RR approximated with OR. | |
| Lee, 7/22/2021, retrospective, South Korea, peer-reviewed, 25 authors, study period 1 January, 2020 - 31 July, 2020. | risk of death, 74.0% lower, RR 0.26, p = 0.046, high activity levels 2 of 11,072 (0.0%), low activity levels 32 of 41,293 (0.1%), NNT 1683, adjusted per study, odds ratio converted to relative risk, model 2,aerobic and muscle strengthening vs. insufficient aerobic and muscle strengthening, multivariable. |
| risk of severe case, 57.8% lower, RR 0.42, p = 0.03, high activity levels 39 of 11,072 (0.4%), low activity levels 273 of 41,293 (0.7%), adjusted per study, odds ratio converted to relative risk, model 2,aerobic and muscle strengthening vs. insufficient aerobic and muscle strengthening, multivariable. | |
| risk of case, 15.6% lower, RR 0.84, p = 0.03, high activity levels 291 of 11,072 (2.6%), low activity levels 1,293 of 41,293 (3.1%), NNT 199, adjusted per study, odds ratio converted to relative risk, model 2,aerobic and muscle strengthening vs. insufficient aerobic and muscle strengthening, multivariable. | |
| Lengelé, 10/23/2021, prospective, Belgium, peer-reviewed, median age 75.6, 8 authors, study period March 2020 - April 2021. | risk of case, 73.6% lower, RR 0.26, p = 0.03, high activity levels 23 of 229 (10.0%), low activity levels 4 of 12 (33.3%), NNT 4.3, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk. |
| Li (B), 2/3/2021, retrospective, United Kingdom, peer-reviewed, 2 authors, per SD increase. | risk of severe case, 81.0% lower, OR 0.19, p = 0.02, RR approximated with OR. |
| risk of hospitalization, 56.0% lower, OR 0.44, p = 0.07, RR approximated with OR. | |
| Lin, 9/21/2021, prospective, multiple countries, peer-reviewed, survey, 19 authors, study period 26 March, 2020 - 8 October, 2020. | risk of case, 47.4% lower, OR 0.53, p = 0.40, inverted to make OR<1 favor high activity levels, exercise ≥1/month vs. exercise <1/month, RR approximated with OR. |
| Lobelo, 5/19/2021, retrospective, Georgia, peer-reviewed, 7 authors, study period 3 March, 2020 - 29 October, 2020. | risk of hospitalization, 20.0% lower, OR 0.80, p = 0.02, high activity levels 2,121, low activity levels 1,648, adjusted per study, inverted to make OR<1 favor high activity levels, active vs. inactive, multivariable, RR approximated with OR. |
| Malisoux, 4/29/2022, retrospective, Luxembourg, peer-reviewed, survey, median age 42.0, 6 authors, study period May 2020 - June 2021, trial NCT04380987 (history). | risk of progression, 63.0% lower, OR 0.37, p = 0.045, high activity levels 115, low activity levels 108, moderate case, >82 vs. <30 MET-hour/week, RR approximated with OR. |
| risk of progression, 52.0% lower, OR 0.48, p = 0.14, high activity levels 116, low activity levels 108, moderate case, >52-82 vs. <30 MET-hour/week, RR approximated with OR. | |
| risk of progression, 43.0% lower, OR 0.57, p = 0.28, high activity levels 113, low activity levels 108, moderate case, 30-52 vs. <30 MET-hour/week, RR approximated with OR. | |
| Maltagliati, 8/11/2021, retrospective, multiple countries, peer-reviewed, survey, 8 authors. | risk of hospitalization, 52.0% lower, OR 0.48, p = 0.02, adjusted per study, model 1, more than once a week vs. hardly ever or never, multivariable, RR approximated with OR. |
| Marcus, 6/17/2021, prospective, multiple countries, peer-reviewed, survey, 12 authors, study period 26 March, 2020 - 3 May, 2020. | risk of symptomatic case, 42.1% lower, RR 0.58, p < 0.001, high activity levels 240 of 10,627 (2.3%), low activity levels 134 of 3,708 (3.6%), NNT 74, adjusted per study, odds ratio converted to relative risk, multivariable. |
| Mohsin, 9/30/2021, retrospective, Bangladesh, peer-reviewed, survey, 10 authors, study period November 2020 - April 2021, excluded in exclusion analyses: unadjusted results with no group details. | risk of severe case, 19.0% lower, RR 0.81, p = 0.04, high activity levels 86 of 258 (33.3%), low activity levels 224 of 544 (41.2%), NNT 13, exercise >30 minutes. |
| risk of severe case, 0.9% higher, RR 1.01, p = 0.91, high activity levels 290 of 698 (41.5%), low activity levels 224 of 544 (41.2%), exercise <30 minutes. | |
| Muñoz-Vergara, 2/13/2024, prospective, USA, peer-reviewed, 7 authors. | risk of hospitalization, 26.7% lower, RR 0.73, p = 0.002, high activity levels 332 of 42,159 (0.8%), low activity levels 203 of 12,405 (1.6%), adjusted per study, odds ratio converted to relative risk, sufficiently active vs. inactive, multivariable, model 3. |
| risk of case, 9.1% lower, RR 0.91, p = 0.004, high activity levels 3,898 of 42,159 (9.2%), low activity levels 1,293 of 12,405 (10.4%), NNT 85, adjusted per study, odds ratio converted to relative risk, sufficiently active vs. inactive, multivariable, model 3. | |
| Nguyen, 9/18/2021, retrospective, Vietnam, peer-reviewed, survey, 17 authors, study period 14 February, 2020 - 2 March, 2020. | risk of symptomatic case, 20.3% lower, RR 0.80, p < 0.001, high activity levels 904 of 2,836 (31.9%), low activity levels 483 of 1,111 (43.5%), NNT 8.6, adjusted per study, odds ratio converted to relative risk, active vs. inactive, COVID-19-like symptoms, multivariable. |
| Park, 2/14/2023, retrospective, South Korea, peer-reviewed, survey, 4 authors, study period 1 January, 2020 - 14 August, 2020. | risk of death, 25.6% lower, OR 0.74, p = 0.08, inverted to make OR<1 favor high activity levels, sufficient vs. insufficient PA, model 3, RR approximated with OR. |
| risk of death, 38.4% lower, OR 0.62, p = 0.02, inverted to make OR<1 favor high activity levels, sufficient vs. insufficient PA, model 2, RR approximated with OR. | |
| risk of case, 7.2% lower, OR 0.93, p = 0.02, inverted to make OR<1 favor high activity levels, sufficient vs. insufficient PA, model 3, RR approximated with OR. | |
| risk of case, 10.4% lower, OR 0.90, p < 0.001, inverted to make OR<1 favor high activity levels, sufficient vs. insufficient PA, model 2, RR approximated with OR. | |
| Paul, 4/13/2022, retrospective, United Kingdom, preprint, survey, 2 authors. | risk of long COVID, 38.1% lower, RR 0.62, p = 0.16, adjusted per study, odds ratio converted to relative risk, 3+ hours per week vs. none, multivariable, model 4, control prevalance approximated with overall prevalence. |
| risk of long COVID, 4.1% lower, RR 0.96, p = 0.89, adjusted per study, odds ratio converted to relative risk, ≤2 hours per week vs. none, multivariable, model 4, control prevalance approximated with overall prevalence. | |
| Pavlidou, 11/9/2023, retrospective, Greece, peer-reviewed, 14 authors. | risk of case, 42.2% lower, OR 0.58, p = 0.001, high activity levels 902, low activity levels 4,295, adjusted per study, inverted to make OR<1 favor high activity levels, high vs. low/moderate IPAQ, multivariable, RR approximated with OR. |
| Pitanga, 10/29/2022, retrospective, Brazil, peer-reviewed, survey, 11 authors. | risk of case, 33.0% lower, OR 0.67, p = 0.05, high activity levels 1,469, low activity levels 1,552, combined results with and without protection practices, RR approximated with OR. |
| Pływaczewska-Jakubowska, 10/24/2022, retrospective, Poland, peer-reviewed, median age 51.0, 5 authors, study period May 2020 - January 2022. | risk of moderate/severe case, 11.0% lower, OR 0.89, p = 0.30, high activity levels 490, low activity levels 1,357, adjusted per study, multivariable, model 3, RR approximated with OR. |
| risk of PASC, 14.0% lower, OR 0.86, p = 0.24, high activity levels 389, low activity levels 1,128, adjusted per study, multivariable, model 3, RR approximated with OR. | |
| Reis, 10/24/2022, retrospective, USA, peer-reviewed, survey, 6 authors, study period December 2020 - February 2021. | risk of hospitalization, 40.7% lower, RR 0.59, p = 0.18, high activity levels 9 of 241 (3.7%), low activity levels 29 of 305 (9.5%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, strength training 2+/week vs. <2, multivariable. |
| Rocha, 12/14/2023, retrospective, Brazil, peer-reviewed, 6 authors, study period December 2020 - March 2021. | risk of PASC, 20.0% lower, OR 0.80, p = 0.05, high activity levels 388, low activity levels 2,096, RR approximated with OR. |
| risk of PASC, 30.0% lower, OR 0.70, p = 0.046, high activity levels 388, low activity levels 2,096, musculoskeletal, RR approximated with OR. | |
| risk of PASC, 39.0% lower, OR 0.61, p = 0.007, high activity levels 388, low activity levels 2,096, neurological, RR approximated with OR. | |
| risk of PASC, 42.0% lower, OR 0.58, p = 0.03, high activity levels 388, low activity levels 2,096, respiratory, RR approximated with OR. | |
| risk of PASC, 5.0% lower, OR 0.95, p = 0.79, high activity levels 388, low activity levels 2,096, sensory, RR approximated with OR. | |
| risk of PASC, 73.0% lower, OR 0.27, p = 0.19, high activity levels 388, low activity levels 2,096, digestive, RR approximated with OR. | |
| Saadeh, 10/30/2021, retrospective, Sweden, peer-reviewed, 6 authors, study period March 2020 - June 2020. | risk of symptomatic case, 9.1% lower, OR 0.91, p = 0.71, high activity levels 362, low activity levels 225, adjusted per study, inverted to make OR<1 favor high activity levels, 2+ symptoms, Table 8, physically active vs. inactive, multivariable, RR approximated with OR. |
| risk of symptomatic case, 3.8% lower, OR 0.96, p = 0.85, high activity levels 362, low activity levels 225, adjusted per study, inverted to make OR<1 favor high activity levels, 1+ symptoms, Table 2, model 2, physically active vs. inactive, multivariable, RR approximated with OR. | |
| Salgado-Aranda, 3/14/2022, retrospective, Spain, peer-reviewed, 15 authors, study period 15 February, 2020 - 15 April, 2020. | risk of death, 83.1% lower, HR 0.17, p = 0.003, high activity levels 4 of 223 (1.8%), low activity levels 41 of 297 (13.8%), NNT 8.3, inverted to make HR<1 favor high activity levels, active vs. sedentary, Cox proportional hazards. |
| Sallis, 4/13/2021, retrospective, USA, peer-reviewed, 8 authors. | risk of death, 59.2% lower, RR 0.41, p = 0.005, high activity levels 11 of 3,118 (0.4%), low activity levels 170 of 6,984 (2.4%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, consistently active vs. consistently inactive, multivariable. |
| risk of ICU admission, 41.5% lower, RR 0.58, p = 0.006, high activity levels 32 of 3,118 (1.0%), low activity levels 195 of 6,984 (2.8%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, consistently active vs. consistently inactive, multivariable. | |
| risk of hospitalization, 53.0% lower, RR 0.47, p < 0.001, high activity levels 99 of 3,118 (3.2%), low activity levels 732 of 6,984 (10.5%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, consistently active vs. consistently inactive, multivariable. | |
| Sanchez, 4/25/2023, retrospective, Spain, peer-reviewed, 3 authors, trial NCT04624048 (history). | risk of symptomatic case, 54.1% lower, OR 0.46, p < 0.001, inverted to make OR<1 favor high activity levels, exercise vs. no exercise before COVID-19, RR approximated with OR. |
| Schmidt, 6/21/2023, retrospective, Germany, peer-reviewed, 8 authors, CoCo-Fakt trial. | risk of case, 31.1% lower, OR 0.69, p = 0.02, high activity levels 956, low activity levels 2,705, adjusted per study, inverted to make OR<1 favor high activity levels, above guidelines vs. below guidelines, multivariable, RR approximated with OR. |
| risk of case, 34.5% lower, OR 0.66, p = 0.02, high activity levels 956, low activity levels 1,113, adjusted per study, inverted to make OR<1 favor high activity levels, above guidelines vs. meeting guidelines, multivariable, RR approximated with OR. | |
| risk of case, 22.7% lower, OR 0.77, p = 0.02, high activity levels 3,658, low activity levels 1,680, adjusted per study, inverted to make OR<1 favor high activity levels, exercise vs. no exercise, multivariable, RR approximated with OR. | |
| risk of case, 21.6% lower, OR 0.78, p = 0.03, high activity levels 3,371, low activity levels 1,716, adjusted per study, inverted to make OR<1 favor high activity levels, moderate-to-vigorous vs. low intensity, multivariable, RR approximated with OR. | |
| Steenkamp, 2/9/2022, retrospective, South Africa, peer-reviewed, 10 authors, study period 19 March, 2020 - 30 June, 2021. | risk of death, 42.0% lower, RR 0.58, p < 0.001, high activity levels 29,469, low activity levels 13,366, adjusted per study, high activity vs. low activity, poisson regression, multivariable. |
| risk of mechanical ventilation, 45.0% lower, RR 0.55, p < 0.001, high activity levels 29,469, low activity levels 13,366, adjusted per study, high activity vs. low activity, poisson regression, multivariable. | |
| risk of ICU admission, 41.0% lower, RR 0.59, p < 0.001, high activity levels 29,469, low activity levels 13,366, adjusted per study, high activity vs. low activity, poisson regression, multivariable. | |
| risk of hospitalization, 34.0% lower, RR 0.66, p < 0.001, high activity levels 29,469, low activity levels 13,366, adjusted per study, high activity vs. low activity, poisson regression, multivariable. | |
| Sutkowska, 6/14/2023, prospective, Poland, peer-reviewed, 14 authors, study period 31 January, 2022 - 11 February, 2022, trial NCT05200767 (history). | risk of death, 62.0% lower, HR 0.38, p = 0.21, high activity levels 71, low activity levels 60, inverted to make HR<1 favor high activity levels, IPAQ 1/2 vs. IPAQ 0, Cox proportional hazards. |
| risk of no recovery, 61.0% lower, HR 0.39, p = 0.19, high activity levels 71, low activity levels 60, IPAQ 1/2 vs. IPAQ 0, Cox proportional hazards. | |
| Tavakol, 2/4/2021, retrospective, Iran, peer-reviewed, 9 authors, study period 20 March, 2020 - 24 April, 2020. | risk of severe case, 68.5% lower, RR 0.31, p = 0.05, high activity levels 3 of 64 (4.7%), low activity levels 19 of 124 (15.3%), NNT 9.4, adjusted per study, odds ratio converted to relative risk, moderate to high activity versus low activity, multivariable. |
| Tret'yakov, 10/26/2020, retrospective, Russia, peer-reviewed, 8 authors, excluded in exclusion analyses: unadjusted results with no group details. | risk of severe case, 98.3% lower, RR 0.02, p = 0.007, high activity levels 0 of 27 (0.0%), low activity levels 53 of 266 (19.9%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| Tsuzuki, 7/5/2022, retrospective, Japan, preprint, 4 authors, study period 1 January, 2022 - 16 May, 2022. | risk of severe case, 56.3% lower, OR 0.44, p < 0.001, high activity levels 3,340, low activity levels 1,528, adjusted per study, inverted to make OR<1 favor high activity levels, good vs. poor physical activity status, multivariable, RR approximated with OR. |
| Wang, 1/31/2024, prospective, United Kingdom, peer-reviewed, 10 authors. | risk of death, 30.0% lower, HR 0.70, p < 0.001, high activity levels 57,930, low activity levels 10,966, adjusted per study, ≥150 min/wk moderate or ≥75 min/wk vigorous vs. < 75 min/wk vigorous, multivariable. |
| risk of hospitalization, 12.0% lower, HR 0.88, p < 0.001, high activity levels 57,930, low activity levels 10,966, adjusted per study, ≥150 min/wk moderate or ≥75 min/wk vigorous vs. < 75 min/wk vigorous, multivariable. | |
| risk of PASC, 14.0% lower, HR 0.86, p < 0.001, high activity levels 57,930, low activity levels 10,966, adjusted per study, ≥150 min/wk moderate or ≥75 min/wk vigorous vs. < 75 min/wk vigorous, multivariable. | |
| Wang (B), 2/6/2023, prospective, USA, peer-reviewed, survey, mean age 64.7, 8 authors, study period April 2020 - November 2021. | risk of PASC, 10.7% lower, RR 0.89, p = 0.20, high activity levels 274 of 691 (39.7%), low activity levels 283 of 594 (47.6%), NNT 13, adjusted per study, inverted to make RR<1 favor high activity levels, ≥210 vs. 0-30, multivariable, model 2. |
| risk of PASC, 49.0% lower, RR 0.51, p = 0.002, high activity levels 188, low activity levels 66, 5 or 6 healthy lifestyle factors vs. 0. | |
| Yates, 2/26/2021, retrospective, United Kingdom, peer-reviewed, 7 authors. | risk of death, 45.3% lower, RR 0.55, p = 0.001, high activity levels 72 of 163,912 (0.0%), low activity levels 62 of 30,119 (0.2%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, multivariable. |
| risk of severe case, 46.7% lower, RR 0.53, p < 0.001, high activity levels 291 of 163,912 (0.2%), low activity levels 180 of 30,119 (0.6%), adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, multivariable. | |
| Young, 12/14/2022, retrospective, USA, peer-reviewed, 7 authors, study period 1 January, 2020 - 31 May, 2021. | risk of death, 74.4% lower, OR 0.26, p < 0.001, high activity levels 11,279, low activity levels 29,099, inverted to make OR<1 favor high activity levels, always active vs. always inactive, RR approximated with OR. |
| risk of death, 65.3% lower, OR 0.35, p < 0.001, high activity levels 11,279, low activity levels 83,452, inverted to make OR<1 favor high activity levels, always active vs. mostly inactive, RR approximated with OR. | |
| risk of death, 47.9% lower, OR 0.52, p < 0.001, high activity levels 11,279, low activity levels 42,490, inverted to make OR<1 favor high activity levels, always active vs. some activity, RR approximated with OR. | |
| risk of death, 35.5% lower, OR 0.65, p = 0.002, high activity levels 11,279, low activity levels 27,871, inverted to make OR<1 favor high activity levels, always active vs. consistently active, RR approximated with OR. | |
| risk of hospitalization, 47.6% lower, OR 0.52, p < 0.001, high activity levels 11,279, low activity levels 29,099, inverted to make OR<1 favor high activity levels, always active vs. always inactive, RR approximated with OR. | |
| risk of hospitalization, 41.9% lower, OR 0.58, p < 0.001, high activity levels 11,279, low activity levels 83,452, inverted to make OR<1 favor high activity levels, always active vs. mostly inactive, RR approximated with OR. | |
| risk of hospitalization, 30.1% lower, OR 0.70, p < 0.001, high activity levels 11,279, low activity levels 42,490, inverted to make OR<1 favor high activity levels, always active vs. some activity, RR approximated with OR. | |
| risk of hospitalization, 20.0% lower, OR 0.80, p < 0.001, high activity levels 11,279, low activity levels 27,871, inverted to make OR<1 favor high activity levels, always active vs. consistently active, RR approximated with OR. | |
| Yuan, 6/20/2021, retrospective, China, peer-reviewed, 9 authors, study period 15 February, 2020 - 14 March, 2020. | risk of death, 90.5% lower, RR 0.09, p = 0.09, high activity levels 0 of 61 (0.0%), low activity levels 6 of 103 (5.8%), NNT 17, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), excluded in exclusion analyses: excessive unadjusted differences between groups. |
| risk of severe case, 70.0% lower, RR 0.30, p = 0.03, high activity levels 3 of 61 (4.9%), low activity levels 26 of 103 (25.2%), NNT 4.9, adjusted per study, inverted to make RR<1 favor high activity levels, odds ratio converted to relative risk, multivariable. | |
| Zhang (C), 12/6/2020, retrospective, United Kingdom, peer-reviewed, 9 authors. | risk of death, 26.0% lower, OR 0.74, p = 0.17, adjusted per study, AMPA, per SD increase, multivariable, RR approximated with OR. |
| risk of case, 18.0% lower, OR 0.82, p = 0.01, adjusted per study, AMPA, per SD increase, multivariable, RR approximated with OR. | |
| Šebić, 7/15/2023, retrospective, Bosnia and Herzegovina, peer-reviewed, 5 authors. | risk of oxygen therapy, 89.5% lower, RR 0.11, p = 0.045, high activity levels 0 of 53 (0.0%), low activity levels 4 of 47 (8.5%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| risk of hospitalization, 91.4% lower, RR 0.09, p = 0.02, high activity levels 0 of 53 (0.0%), low activity levels 5 of 47 (10.6%), NNT 9.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). | |
| risk of progression, 83.9% lower, RR 0.16, p < 0.001, high activity levels 4 of 53 (7.5%), low activity levels 22 of 47 (46.8%), NNT 2.5, pneumonia. | |
| no recovery, 47.3% lower, RR 0.53, p < 0.001, high activity levels 22 of 53 (41.5%), low activity levels 37 of 47 (78.7%), NNT 2.7, day 14. |
Laukkanen et al., Objectively Assessed Cardiorespiratory Fitness and All-Cause Mortality Risk, Mayo Clinic Proceedings, doi:10.1016/j.mayocp.2022.02.029.
Fernandez et al., Intrahospital supervised exercise training improves survival rate among hypertensive COVID-19 patients, Journal of Applied Physiology, doi:10.1152/japplphysiol.00544.2022.
Rahmati et al., Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: A systematic review and meta-analysis, Reviews in Medical Virology, doi:10.1002/rmv.2349.
Ezzatvar et al., Physical activity and risk of infection, severity and mortality of COVID-19: a systematic review and non-linear dose–response meta-analysis of data from 1 853 610 adults, British Journal of Sports Medicine, doi:10.1136/bjsports-2022-105733.
Sittichai et al., Effects of physical activity on the severity of illness and mortality in COVID-19 patients: A systematic review and meta-analysis, Frontiers in Physiology, doi:10.3389/fphys.2022.1030568.
Liu et al., Baseline physical activity and the risk of severe illness and mortality from COVID-19: A dose–response meta-analysis, Preventive Medicine Reports, doi:10.1016/j.pmedr.2023.102130.
Halabchi et al., Association between physical activity and risk of COVID-19 infection or clinical outcomes of the patients with COVID-19; A systematic review and meta-analysis, Journal of Preventive Medicine and Hygiene, doi:10.15167/2421-4248/jpmh2023.64.2.2625.
Li et al., Association of physical activity and the risk of COVID-19 hospitalization: a dose-response meta-analysis, medRxiv, doi:10.1101/2022.06.22.22276789.
Guthold et al., Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants, The Lancet Global Health, doi:10.1016/S2214-109X(18)30357-7.
Nieman et al., The compelling link between physical activity and the body's defense system, Journal of Sport and Health Science, doi:10.1016/j.jshs.2018.09.009.
Kunutsor et al., High fitness levels, frequent sauna bathing and risk of pneumonia in a cohort study: Are there potential implications for COVID‐19?, European Journal of Clinical Investigation, doi:10.1111/eci.13490.
Zeraatkar et al., Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review, BMJ Medicine, doi:10.1136/bmjmed-2022-0003091.
Davidson et al., No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.
Brawner et al., Inverse Relationship of Maximal Exercise Capacity to Hospitalization Secondary to Coronavirus Disease 2019, Mayo Clinic Proceedings, doi:10.1016/j.mayocp.2020.10.003.
de Souza et al., Association of physical activity levels and the prevalence of COVID-19-associated hospitalization, Journal of Science and Medicine in Sport, doi:10.1016/j.jsams.2021.05.011.
Hegazy et al., Beneficial role of healthy eating Index-2015 score & physical activity on COVID-19 outcomes, BMC Nutrition, doi:10.1186/s40795-023-00727-8.
Huang et al., Reduced Sleep in the Week Prior to Diagnosis of COVID-19 is Associated with the Severity of COVID-19, Nature and Science of Sleep, doi:10.2147/NSS.S263488.
Kontopoulou et al., Exercise Preferences and Benefits in Patients Hospitalized with COVID-19, Journal of Personalized Medicine, doi:10.3390/jpm12040645.
Mohsin et al., Lifestyle and Comorbidity-Related Risk Factors of Severe and Critical COVID-19 Infection: A Comparative Study Among Survived COVID-19 Patients in Bangladesh, Infection and Drug Resistance, doi:10.2147/IDR.S331470.
Tret'yakov et al., COVID-19 in individuals adapted to aerobic exercise, Pulmonologiya, doi:10.18093/0869-0189-2020-30-5-553-560.
Yuan et al., Does pre-existent physical inactivity have a role in the severity of COVID-19?, Therapeutic Advances in Respiratory Disease, doi:10.1177/17534666211025221.
Singh et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045.
Zhang et al., Effects of the High-Intensity Early Mobilization on Long-Term Functional Status of Patients with Mechanical Ventilation in the Intensive Care Unit, Critical Care Research and Practice, doi:10.1155/2024/4118896.
Nindenshuti et al., Changes in Diet, Physical Activity, Alcohol Consumption, and Tobacco Use in Adults During the COVID-19 Pandemic: A Systematic Review, INQUIRY: The Journal of Health Care Organization, Provision, and Financing, doi:10.1177/00469580231175780.
ÓhAiseadha et al., Unintended Consequences of COVID-19 Non-Pharmaceutical Interventions (NPIs) for Population Health and Health Inequalities, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph20075223.
Larenas-Linnemann et al., Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions, World Allergy Organization Journal, doi:10.1016/j.waojou.2020.100476.
Dugied et al., Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization, Communications Biology, doi:10.1038/s42003-025-07933-z.
Malone et al., Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
Murigneux et al., Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly, Nature Communications, doi:10.1038/s41467-024-44958-0.
Lv et al., Host proviral and antiviral factors for SARS-CoV-2, Virus Genes, doi:10.1007/s11262-021-01869-2.
Lui et al., Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling, Virology, doi:10.1128/mbio.00392-24.
Niarakis et al., Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
Katiyar et al., SARS-CoV-2 Assembly: Gaining Infectivity and Beyond, Viruses, doi:10.3390/v16111648.
Wu et al., Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition, RNA Biology, doi:10.1080/15476286.2024.2433830.
Hazan et al., Probiotics Counterfeit! Study Finds Most Labels Mislead Customers, American Journal of Gastroenterology, doi:10.14309/01.ajg.0000950600.34429.5f.
Zhang (B) et al., What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.
Altman (B) et al., How to obtain the confidence interval from a P value, BMJ, doi:10.1136/bmj.d2090.
Sweeting et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Statistics in Medicine, doi:10.1002/sim.1761.
Treanor et al., Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
McLean et al., Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
af Geijerstam et al., Fitness, strength and severity of COVID-19: a prospective register study of 1 559 187 Swedish conscripts, BMJ Open, doi:10.1136/bmjopen-2021-051316.
Ahmadi et al., Lifestyle risk factors and infectious disease mortality, including COVID-19, among middle aged and older adults: Evidence from a community-based cohort study in the United Kingdom, Brain, Behavior, and Immunity, doi:10.1016/j.bbi.2021.04.022.
Akbar et al., The Association between Lifestyle Factors and COVID-19: Findings from Qatar Biobank, Nutrients, doi:10.3390/nu16071037.
Almansour et al., The Influence of Physical Activity on COVID-19 Prevention Among Quarantined Individuals: A Case–Control Study, Journal of Multidisciplinary Healthcare, doi:10.2147/JMDH.S352753.
Antunes et al., The influence of physical activity level on the length of stay in hospital in older men survivors of COVID-19, Sport Sciences for Health, doi:10.1007/s11332-022-00948-7.
Baynouna AlKetbi et al., Risk Factors for SARS-CoV-2 Infection Severity in Abu Dhabi, Journal of Epidemiology and Global Health, doi:10.1007/s44197-021-00006-4.
Beydoun et al., Socio-demographic, lifestyle and health characteristics as predictors of self-reported Covid-19 history among older adults: 2006-2020 Health and Retirement Study, American Journal of Infection Control, doi:10.1016/j.ajic.2022.02.021.
Bielik et al., A Possible Preventive Role of Physically Active Lifestyle during the SARS-CoV-2 Pandemic; Might Regular Cold-Water Swimming and Exercise Reduce the Symptom Severity of COVID-19?, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18137158.
Brandenburg et al., Does Higher Self-Reported Cardiorespiratory Fitness Reduce the Odds of Hospitalization From COVID-19?, Journal of Physical Activity and Health, doi:10.1123/jpah.2020-0817.
Cardoso et al., Patterns of physical activity and SARS-CoV-2 severe pneumonia: A case–control study, Medicina Clínica, doi:10.1016/j.medcli.2023.04.031.
Cho et al., Physical Activity and the Risk of COVID-19 Infection and Mortality: A Nationwide Population-Based Case-Control Study, Journal of Clinical Medicine, doi:10.3390/jcm10071539.
Christensen et al., The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study, PLOS ONE, doi:10.1371/journal.pone.0250508.
Ekblom-Bak et al., Cardiorespiratory fitness and lifestyle on severe COVID-19 risk in 279,455 adults: a case control study, International Journal of Behavioral Nutrition and Physical Activity, doi:10.1186/s12966-021-01198-5.
Feter et al., Physical activity and long COVID: findings from the Prospective Study About Mental and Physical Health in Adults cohort, Public Health, doi:10.1016/j.puhe.2023.05.011.
Frish et al., The Association of Weight Reduction and Other Variables after Bariatric Surgery with the Likelihood of SARS-CoV-2 Infection, Journal of Clinical Medicine, doi:10.3390/jcm12124054.
Gao et al., The impact of individual lifestyle and status on the acquisition of COVID-19: A case—Control study, PLOS ONE, doi:10.1371/journal.pone.0241540.
Gilley et al., Risk Factors for COVID-19 in College Students Identified by Physical, Mental, and Social Health Reported During the Fall 2020 Semester: Observational Study Using the Roadmap App and Fitbit Wearable Sensors, JMIR Mental Health, doi:10.2196/34645.
Green et al., A higher frequency of physical activity is associated with reduced rates of SARS-CoV-2 infection, European Journal of General Practice, doi:10.1080/13814788.2022.2138855.
Halabchi (B) et al., Regular Sports Participation as a Potential Predictor of Better Clinical Outcome in Adult Patients With COVID-19: A Large Cross-Sectional Study, Journal of Physical Activity and Health, doi:10.1123/jpah.2020-0392.
Hamdan et al., Risk factors associated with hospitalization owing to COVID-19: a cross-sectional study in Palestine, Journal of International Medical Research, doi:10.1177/03000605211064405.
Hamer et al., Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK, Brain, Behavior, and Immunity, doi:10.1016/j.bbi.2020.05.059.
Hamrouni et al., Associations of obesity, physical activity level, inflammation and cardiometabolic health with COVID-19 mortality: a prospective analysis of the UK Biobank cohort, BMJ Open, doi:10.1136/bmjopen-2021-055003.
Hegazy (B) et al., Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity, British Journal of Nutrition, doi:10.1017/S0007114521001926.
Ho et al., Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study, BMJ Open, doi:10.1136/bmjopen-2020-040402.
Holt et al., Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK), Thorax, doi:10.1136/thoraxjnl-2021-217487.
Kapusta et al., Do selected lifestyle parameters affect the severity and symptoms of COVID-19 among elderly patients? The retrospective evaluation of individuals from the STOP-COVID registry of the PoLoCOV study, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.12.008.
Latorre-Román et al., Protective role of physical activity patterns prior to COVID-19 confinement with the severity/duration of respiratory pathologies consistent with COVID-19 symptoms in Spanish populations, Research in Sports Medicine, doi:10.1080/15438627.2021.1937166.
Lee et al., Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study, British Journal of Sports Medicine, doi:10.1136/bjsports-2021-104203.
Lengelé et al., Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults, Aging Clinical and Experimental Research, doi:10.1007/s40520-021-01991-z.
Li (B) et al., Modifiable lifestyle factors and severe COVID-19 risk: a Mendelian randomisation study, BMC Medical Genomics, doi:10.1186/s12920-021-00887-1.
Lin et al., Predictors of incident SARS-CoV-2 infections in an international prospective cohort study, BMJ Open, doi:10.1136/bmjopen-2021-052025.
Lobelo et al., Clinical, behavioural and social factors associated with racial disparities in COVID-19 patients from an integrated healthcare system in Georgia: a retrospective cohort study, BMJ Open, doi:10.1136/bmjopen-2020-044052.
Malisoux et al., Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort study, BMJ Open, doi:10.1136/bmjopen-2021-057863.
Maltagliati et al., Muscle strength explains the protective effect of physical activity against COVID-19 hospitalization among adults aged 50 years and older, Journal of Sports Sciences, doi:10.1080/02640414.2021.1964721.
Marcus et al., Predictors of incident viral symptoms ascertained in the era of COVID-19, PLOS ONE, doi:10.1371/journal.pone.0253120.
Muñoz-Vergara et al., Prepandemic Physical Activity and Risk of COVID-19 Diagnosis and Hospitalization in Older Adults, JAMA Network Open, doi:10.1001/jamanetworkopen.2023.55808.
Nguyen et al., Single and Combinative Impacts of Healthy Eating Behavior and Physical Activity on COVID-19-like Symptoms among Outpatients: A Multi-Hospital and Health Center Survey, Nutrients, doi:10.3390/nu13093258.
Park et al., Pre-pandemic physical activity as a predictor of infection and mortality associated with COVID-19: Evidence from the National Health Insurance Service, Frontiers in Public Health, doi:10.3389/fpubh.2023.1072198.
Paul et al., Health behaviours the month prior to COVID-19 infection and the development of self-reported long COVID and specific long COVID symptoms: A longitudinal analysis of 1,811 UK adults, medRxiv, doi:10.1101/2022.04.12.22273792.
Pavlidou et al., Association of COVID-19 Infection with Sociodemographic, Anthropometric and Lifestyle Factors: A Cross-Sectional Study in an Older Adults’ Population Aged over 65 Years Old, Diseases, doi:10.3390/diseases11040165.
Pitanga et al., Leisure Time Physical Activity and SARS-CoV-2 Infection among ELSA-Brasil Participants, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph192114155.
Pływaczewska-Jakubowska et al., Lifestyle, course of COVID-19, and risk of Long-COVID in non-hospitalized patients, Frontiers in Medicine, doi:10.3389/fmed.2022.1036556.
Reis et al., The Association between Lifestyle Risk Factors and COVID-19 Hospitalization in a Healthcare Institution, American Journal of Lifestyle Medicine, doi:10.1177/15598276221135541.
Rocha et al., Physical activity status prevents symptoms of long covid: Sulcovid-19 survey, BMC Sports Science, Medicine and Rehabilitation, doi:10.1186/s13102-023-00782-5.
Saadeh et al., Associations of pre-pandemic levels of physical function and physical activity with COVID-19-like symptoms during the outbreak, Aging Clinical and Experimental Research, doi:10.1007/s40520-021-02006-7.
Salgado-Aranda et al., Influence of Baseline Physical Activity as a Modifying Factor on COVID-19 Mortality: A Single-Center, Retrospective Study, Infectious Diseases and Therapy, doi:10.1007/s40121-021-00418-6.
Sallis et al., Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients, British Journal of Sports Medicine, doi:10.1136/bjsports-2021-104080.
Sanchez et al., Influence of Physical Exercise on the Severity of COVID-19, Fisioterapia, doi:10.1016/j.ft.2023.04.003.
Schmidt et al., Self-Reported Pre-Pandemic Physical Activity and Likelihood of COVID-19 Infection: Data from the First Wave of the CoCo-Fakt Survey, Sports Medicine - Open, doi:10.1186/s40798-023-00592-6.
Steenkamp et al., Small steps, strong shield: directly measured, moderate physical activity in 65 361 adults is associated with significant protective effects from severe COVID-19 outcomes, British Journal of Sports Medicine, doi:10.1136/bjsports-2021-105159.
Sutkowska et al., Physical Activity Modifies the Severity of COVID-19 in Hospitalized Patients—Observational Study, Journal of Clinical Medicine, doi:10.3390/jcm12124046.
Tavakol et al., Relationship between physical activity, healthy lifestyle and COVID-19 disease severity; a cross-sectional study, Journal of Public Health, doi:10.1007/s10389-020-01468-9.
Tsuzuki et al., Impact of dementia, living in a long-term care facility, and physical activity status on COVID-19 severity in older adults, medRxiv, doi:10.1101/2022.07.01.22277144.
Wang et al., Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death, Nature Communications, doi:10.1038/s41467-024-50495-7.
Wang (B) et al., Adherence to Healthy Lifestyle Prior to Infection and Risk of Post–COVID-19 Condition, JAMA Internal Medicine, doi:10.1001/jamainternmed.2022.6555.
Yates et al., Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank, International Journal of Obesity, doi:10.1038/s41366-021-00771-z.
Young et al., Associations of Physical Inactivity and COVID-19 Outcomes Among Subgroups, American Journal of Preventive Medicine, doi:10.1016/j.amepre.2022.10.007.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.